Richard J Robbins

Summary

Affiliation: Texas Medical Center
Country: USA

Publications

  1. ncbi request reprint Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning
    Richard J Robbins
    Department of Medicine, Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Endocrinol Metab 91:498-505. 2006
  2. ncbi request reprint Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine
    Richard J Robbins
    Endocrine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Thyroid 16:1121-30. 2006
  3. ncbi request reprint Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma
    Richard J Robbins
    Endocrinology Service, Department of Medicine, Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Clin Endocrinol Metab 89:6010-6. 2004
  4. doi request reprint Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal
    R Michael Tuttle
    Division of Endocrinology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Nucl Med 49:764-70. 2008
  5. ncbi request reprint A sequence-specific exopeptidase activity test (SSEAT) for "functional" biomarker discovery
    Josep Villanueva
    Protein Center, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Mol Cell Proteomics 7:509-18. 2008
  6. ncbi request reprint Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer
    R Michael Tuttle
    Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 47:1587-91. 2006
  7. ncbi request reprint Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software
    George Sgouros
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Nucl Med 45:1366-72. 2004
  8. ncbi request reprint A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation
    Richard J Robbins
    Endocrinology Service, Department of Medicine, Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 43:1482-8. 2002
  9. ncbi request reprint Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients
    Daniel A Pryma
    Nuclear Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Nucl Med 47:1260-6. 2006
  10. ncbi request reprint Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age
    Josep Villanueva
    Protein Center, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mol Cell Proteomics 5:1840-52. 2006

Collaborators

Detail Information

Publications22

  1. ncbi request reprint Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning
    Richard J Robbins
    Department of Medicine, Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Endocrinol Metab 91:498-505. 2006
    ..We hypothesized that the metabolic activity of metastatic lesions, as defined by retention of 2-[(18)F]fluoro-2-deoxyglucose (FDG), would correlate with prognosis...
  2. ncbi request reprint Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine
    Richard J Robbins
    Endocrine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Thyroid 16:1121-30. 2006
    ..Two patients had serious adverse events that were thought to be related to rhTSH. rhTSH elevates serum TSH and facilitates radioiodine uptake in patients who cannot produce endogenous TSH or who cannot tolerate hypothyroidism...
  3. ncbi request reprint Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma
    Richard J Robbins
    Endocrinology Service, Department of Medicine, Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Clin Endocrinol Metab 89:6010-6. 2004
    ..We conclude that the location and volume of metastases influence basal Tg, but not its responsiveness to rhTSH, whereas the histological type of carcinoma influences both basal Tg and responsiveness to rhTSH...
  4. doi request reprint Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal
    R Michael Tuttle
    Division of Endocrinology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Nucl Med 49:764-70. 2008
    ..However, no published study has determined the effectiveness of rhTSH preparations on the important endpoint of disease recurrence...
  5. ncbi request reprint A sequence-specific exopeptidase activity test (SSEAT) for "functional" biomarker discovery
    Josep Villanueva
    Protein Center, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Mol Cell Proteomics 7:509-18. 2008
    ..The test all but eliminates reproducibility problems related to sample collection, storage, and handling as well as to possible variability in endogenous peptide precursor levels because of hemostatic alterations in cancer patients...
  6. ncbi request reprint Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer
    R Michael Tuttle
    Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 47:1587-91. 2006
    ....
  7. ncbi request reprint Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software
    George Sgouros
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Nucl Med 45:1366-72. 2004
    ..This input has typically been obtained from SPECT and planar imaging studies. The objective was to implement and evaluate PET-based, patient-specific, 3D dosimetry for thyroid cancer patients...
  8. ncbi request reprint A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation
    Richard J Robbins
    Endocrinology Service, Department of Medicine, Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 43:1482-8. 2002
    ..During this same time period, other patients at our center were prepared for RRA by hormone withdrawal...
  9. ncbi request reprint Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients
    Daniel A Pryma
    Nuclear Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Nucl Med 47:1260-6. 2006
    ..However, there is limited information with regard to the true diagnostic accuracy and prognostic value of 18F-FDG PET in this disease...
  10. ncbi request reprint Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age
    Josep Villanueva
    Protein Center, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mol Cell Proteomics 5:1840-52. 2006
    ....
  11. ncbi request reprint Coming of age: recombinant human thyroid-stimulating hormone as a preparation for (131)i therapy in thyroid cancer
    Richard J Robbins
    Memorial Sloan Kettering Cancer Center, New York, New York
    J Nucl Med 44:1069-71. 2003
  12. doi request reprint The value of positron emission tomography (PET) in the management of patients with thyroid cancer
    Richard J Robbins
    Endocrine Division, Department of Medicine, The Methodist Hospital, Houston, TX 77030, USA
    Best Pract Res Clin Endocrinol Metab 22:1047-59. 2008
    ..The majority of the published studies to date have used 18F-fluoro-deoxyglucose (FDG) as the PET isotope, and unless specifically noted, all references to PET scanning will imply that this tracer has been used...
  13. ncbi request reprint Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma?
    Richard J Robbins
    Endocrinology Service, Department of Medicine, Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Endocrinol Metab 87:3242-7. 2002
    ..We conclude that the stimulated Tg alone is not sufficient by itself to screen unselected patients, but that it may be sufficient in low risk patients, especially those who have had a prior negative DxWBS...
  14. ncbi request reprint Clinical review 156: Recombinant human thyrotropin and thyroid cancer management
    Richard J Robbins
    Endocrine Service, Division of General Medicine, Department of Medicine, and Medical Library Nathan Cummings Center, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Clin Endocrinol Metab 88:1933-8. 2003
  15. ncbi request reprint The evolving role of (131)I for the treatment of differentiated thyroid carcinoma
    Richard J Robbins
    Endocrine Service, Division of General Medicine, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Nucl Med 46:28S-37S. 2005
    ..131)I will continue to be a major weapon in the fight against metastatic thyroid carcinoma. Its future role will be modified by expanding knowledge of its relative risks and benefits...
  16. doi request reprint Hürthle cell carcinoma of the thyroid presenting as thyrotoxicosis
    Harsha Karanchi
    Department of Medicine, The Methodist Hospital, Houston, Texas 77030, USA
    Endocr Pract 18:e5-9. 2012
    ..To report a case of hyperthyroidism associated with Hürthle cell carcinoma and to review the literature regarding this relationship...
  17. pmc Correcting common errors in identifying cancer-specific serum peptide signatures
    Josep Villanueva
    Protein Center, Molecular Biology Program, Engineering Resource Laboratory, Department of Clinical Laboratories, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Proteome Res 4:1060-72. 2005
    ..g., gender, age, genetics, environmental, dietary, and other factors) may now be addressed...
  18. pmc Expanding indications for recombinant human TSH in thyroid cancer
    Bryan R Haugen
    Thyroid 18:687-94. 2008
  19. ncbi request reprint Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib
    Darren R Feldman
    J Natl Cancer Inst 99:974-5; author reply 976-7. 2007
  20. ncbi request reprint Distilling cancer biomarkers from the serum peptidome: high technology reading of tea leaves or an insight to clinical systems biology?
    Richard J Robbins
    J Clin Oncol 23:4835-7. 2005
  21. ncbi request reprint Statins sentence thyroid cancer cells to death rho
    Richard J Robbins
    J Clin Endocrinol Metab 88:3019-20. 2003
  22. ncbi request reprint Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial
    Andrew R Hoffman
    Veterans Affairs Palo Alto Health Care System and Stanford University, Palo Alto, California 94304, USA
    J Clin Endocrinol Metab 89:2048-56. 2004
    ..GH treatment was generally well tolerated. Subjects with AGHD should receive individualized GH therapy to maintain IGF-I between the mean value and +2 SD and improve body composition and cardiovascular risk factors...